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Iron Uptake in Human Keratinocytes Exposed to Photodegraded Nifedipine. Alison
B. Gruen, Jing Zhou, Kathryn Morton *, and Leonard M. Milstone, Depts. Dermatology
and Radiology*, Yale University School of Medicine, and VA Medical Center, West
Haven, CT. and Portland, OR*.

Photodegraded nifedipine (PDN) has been shown to increase uptake of non¬
transferrin bound iron in erythroid cells. We investigated the ability of photodegraded
nifedipine to mediate iron transport in human keratinocytes with the underlying goal of
exploiting the process of epidermal desquamation for the purpose of eliminating toxic
chemicals such as iron. Nifedipine was exposed to direct outdoor daylight for 1 hour to
allow for the formation of the active nitroso metabolite. The adequacy of photo¬
degradation was confirmed by thin-layer chromatography on silica gel. Keratinocytes
were incubated at 37°C with 15 uM 'qFe and either 25 uM PDN or ethanol. The
monolayer was trypsinized and centrifuged through a dibutylphthalate:paraffin oil
column. Cell pellets were collected for gamma counting and protein assay. PDN
stimulated a 20-fold increase in iron uptake in 30 minutes relative to controls. The
keratinoctye’s ability to accumulate and retain iron was tested by pulsing cells for 1 hour
in 25 uM PDN and 20 uM Fe on four successive days. After a four day washout, the total
iron content of keratinocytes - measured by inductively coupled plasma emission
spectroscopy - was 3-fold greater in PDN-treated dishes than in controls. The effect of
time, dose, and cellular differentiation were similarly investigated. PDN provides an
effective method for loading iron into keratinocytes.
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Introduction

A primary function of the epidermis is to provide a renewable barrier, particularly
to water loss. The epidermal barrier is maintained in delicate equilibrium between the
production and loss of its composite cells. As spent keratinocytes and barrier remnants
desquamate from the surface, regeneration of cells at the basal layer ensures a continually
renewing supply.

The epidermis is morphologically and functionally stratified.

Proliferating cells are restricted to the basal or innermost cell layer.

As these cells

progressively differentiate and traverse the epidermis, they are shed or desquamated from
the most superficial layer of the epidermis, the stratum comeum.
basal cell to squame normally occurs in 28 days.

The transition from

In hyperproliferative disorders of the

epidermis, like psoriasis, epidermal renewal is accelerated 6-fold.
Epidermal renewal naturally has metabolic consequences in the form of the
cellular contents lost to the environment with desquamated cells.

One gram of dry

weight is desquamated daily from normal skin, and up to 12-15 grams per day in psoriatic
erythroderma (1).

Studies on protein and mineral content of scale suggest that

erythrodermic losses are insufficient to cause negative nitrogen balance (1), but may
result in iron deficiency by cellular iron losses (2). The degree to which the epidermis
participates in body iron balance is under-appreciated.
eliminated daily through the skin (3, 4, 5).

20-25% of absorbed iron is

These epidermal losses result mainly from

cellular desquamation rather than sweating (6, 7).
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Much of our present understanding of epidermal mineral loss comes from studies
performed in the 1950s, 60s, and 70s.

There is abundant information on the potential

burden of minerals but few studies on the potential metabolic benefits.

Certainly, the

boundaries of epidermal function have been challenged. Through genetic engineering the
epidermis has been modified for the secretion of hormones and growth factors (8),
modulation of immune function (9) and the inactivation of toxic metabolic products. (10).
In the presence of such innovation, it is surprising that one of the most basic qualities of
the epidermis—desquamation—was overlooked.

The unique process of desquamation

makes it an appealing site for further investigation. Essentially, desquamation represents
a fixed route of loss to the environment.

Certainly there are medical diseases and

conditions that would benefit from such an alternative excretory pathway. The question
then arises: Could desquamation be exploited to eliminate toxic chemicals like lead, iron,
or copper from the body?
For several reasons, iron and diseases of iron overload represent a sensible
preliminary model to investigate this possibility.

Iron overload presents a clinically

significant problem with imperfect therapies; there is an abundance of knowledge about
body iron homeostasis; and, such research would advance our understanding of the
particular role of the epidermis in iron metabolism.

Because this represents a novel

approach to these diseases and to desquamation in general, there is no specific scientific
literature. A wealth of information, however, does exist on body iron metabolism and
epidermal desquamation.
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Iron Metabolism - Then and Now
Iron actually has a long and glamorous history. It’s rise to historical preeminence
came with the advent of the Iron Age. Unbeknownst to many, this evolution precipitated
the fall of the ancient Egyptian civilization.

Much of Egypt’s power was afforded by

their control of large deposits of copper (the main ingredient in bronze) in the Sinai
Peninsula. By the thirteenth century B.C. other societies had discovered and successfully
employed iron, a harder and more abundant element, in tools and weapons allowing
larger, better equipped armies. The copper-clad Egyptian army was unable to meet the
challenge of its new foe (11).
This heroic motif in iron chemistry reappears centuries later in mythology. In the
Greco-Roman tradition, iron was associated with the god of war, known to the Greeks as
Ares and to the Romans as Mars.

Other myths, including that of Jason and the

Argonauts, are rife with images of iron as a source of strength, potency, and healing (11).
On a softer side iron, or rather its deficiency, created the romantic, though sickly
image of “lovesickness” because of the demographics of its sufferers.

Naturally,

marriage was thought to be the best salve. The ultimate causal association between iron
deficiency and the anemic appearance of centuries of young, malnourished women,
unfolded slowly and with amusingly clever misdiagnoses.

Because of the unexplained

green tint that iron deficiency gave pale skin, it was medically described as ‘chlorosis’
(from the Greek word for green) or more popularly, “greensickness.”

Writers from

Hippocrates to Shakespeare alluded to the disease. It was not until the late 17th Century
that the link between iron deficiency and ‘chlorosis’ was elucidated. Thomas Sydenham
of London in late 17th century is credited with the discovery (11).
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One of the predominant themes in iron metabolism is of duality, of iron as both an
essential nutrient and a toxin.

Early insight into the contrasting properties of iron are

present in the first encyclopedia The Historic of the World, 1st century A.D. by Gaius
Plinus Secundus. An old English translation dating to 1601 notes:

“It remaineth now to discourse of ... yron, a mettal, which wee
may well say is both the best and the worst... in the world: For
with the help of yron we breake up and ear the ground, we plant
and plot our groves, we set our hortyards... by means of yron and
steele we build our houses, new quarries.. .yea and in one word, we
use it to all other necessarie uses of this life. Contrariwise, the
same yron serveth for warres, murders, robberies...this I take to be
the wickedest invention that ever was devised by the head of
man...” (12)

The paradox of iron metabolism is apparent still.

It is an essential nutrient

required by all organisms for growth and metabolic pathways. Iron dependent processes
include DNA synthesis, ATP generation, and hemoglobin and myoglobin function.
However, iron is also a potential toxin, capable of catalyzing free radical formation
resulting in damage to DNA and cellular membranes.

The unique chemistry of iron

presents a challenge as well. Two valencies account for iron’s divergent properties: the
participation in biologic redox reactions vs. a tendency towards free radical formation,
the solubility of some of its compounds vs. the insolubility of others.

In an oxidizing

environment, iron exists in the largely insoluble ferric form, making its transport,
solubilization and storage a matter of importance for all organisms (13, 14).
To insure appropriate body iron content, body iron metabolism is well balanced.
Under normal circumstances, iron does not accumulate in the body.

Of the average

ingested iron load of 10-20 mg/day, only 1 mg is absorbed, an amount which increases
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with vitamin C or alcohol. To avoid accumulation of iron, 1 mg per day must therefore
be excreted. Approximately 0.6 mg is lost in feces, 0.2 - 0.3 mg is lost from the skin,
and less than 0.1 mg is lost in urine (15).

During the years between menarche and

menopause, women’s iron losses increase to 2 mg/day with a compensatory increase in
absorption to about 1.5 mg/day (16,14).
seemingly small daily exchanges.
men, 3 g in women.

Total body iron content is large relative to

Normal body iron stores are approximately 4 g in

These stores are balanced among functional compounds, storage

complexes and transport chelates. The distribution of iron in tissue, as adapted from a
recent NEJM review on iron metabolism, is shown in Figure 1 (17). Most of this iron,
between 35-40 mg per kg body weight, represents functional iron, 75% of which is in
hemoglobin.

Another 0-20 mg per kg iron exists as a reserve form in ferritin and

hemosiderin—two major iron storage proteins (15).
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Fig. 1. Distribution of iron in adults. In the balanced state, 1 to 2 mg or iron enters and
leaves the body daily. Dietary iron is absorbed in the duodenum and then circulates in
the plasma bound to transferrin. Most of the iron in the body is incorporated into
hemoglobin in erythroid precursors and mature red cells. Approximately 10-15 percent is
present in muscle fibers (in myoglobin) and other tissues (enzymes and cytochromes).
Iron is stored in parenchymal cells of the liver and reticuloendothelial macrophages.
These macrophages provide most of the usable iron by degrading hemoglobin in
senescent erythrocytes and reloading ferric iron onto transferrin for delivery to cells.

Diseases of Iron Overload
In certain disease states this homeostasis is challenged and iron accumulates
abnormally in the body.

Systemic iron overload results in the deposition of toxic
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amounts of iron in parenchymal cells. The intracellular iron pool expands uncontrollably
surpassing not only transferrin binding but also the sequestering capacity of ferritin. The
emergence of this unbound toxic form of iron promotes the formation of free hydroxyl
radicals that damage cellular membranes, DNA and proteins (18).

Diseases resulting

from iron overload can be either primary or secondary—resulting from a recessive
disease of iron transport or from excess dietary iron and diseases requiring frequent blood
transfusions.
Hereditary hemochromatosis (HH), unbeknownst to many, is the most common
genetic disorder in the U.S. Caucasian population. The gene frequency in this population
is 5-10%.

A homozygote genotype occurs with a frequency of one in 250 persons,

though there is variable phenotypic expression (18).

Ninety percent of Caucasian

hereditary hemochromatosis patients are homozygous for the same mutation (C282Y) in
the HFE gene—the mutant protein in HH.

Studies in HFE knockout mice and in B2-

microglobulin knockout mice (a mutation which inhibits cell surface expression of HFE)
document a pattern of iron overload similar to that in hemochromatosis (19, 20, 21, 22).
The function of the HFE protein in iron absorption is unclear. One recent study showed
that the wild type HFE protein decreases the affinity of the transferrin receptor for
transferrin, raising the possibility that a loss of down-regulation of transferrin-mediated
iron transport may be responsible for HH (23). Other studies reach different conclusions
as to the nature of HFE participation (24).

The exact interaction between HFE, the

transferrin receptor, and other cellular iron transporters awaits further illumination.
The end result is a failure to appropriately regulate intestinal iron absorption.
Patients with hemochromatosis absorb 2 to 3 times the amount of daily dietary iron as
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normal individuals, approximately 4 mg per day. Because there is no known excretory
mechanism for excess iron, its levels in the body—normally constant—begin to rise.
Parenchymal iron deposition occurs as transferrin saturates. An elevation of transferrin
saturation is usually present by adolescence, but is rarely detected before clinical
symptoms occurring decades later prompt an investigation. The clinical picture in HH is
one of slow, insidious progression with clinical manifestations occurring after total body
iron approaches 20 grams—the normal level being 3-5 grams (15). In affected men this
occurs by ages 40-60. Women present later because of a physiologic iron losses during
menstruation, childbirth, and lactation (25).

Initial manifestations include fatigue, skin

hypergimentation, arthralgias, and erectile dysfunction.

With disease progression,

elevated hepatic iron causes tender hepatomegaly, then ultimately cirrhosis and, not
uncommonly, hepatocellular carcinoma—an
hemoochromatosis-related deaths (26).

outcome responsible

for

10-30%

of

Iron deposition in endocrine organs results in

hypogonadism, hypothyroidism, and diabetes.

In the heart it causes cardiomyopathy

(27).
The progressive nature of the disease makes early recognition and initiation of
therapy imperative.

Unfortunately the classic clinical description of the disease as

‘bronze-diabetes’ is misleading because it depicts the end-stage of disease where organ
failure is imminent (27). As a result, physicians often miss an earlier, and perhaps, life¬
saving diagnosis. A landmark study by Niederau, 1985 determined that the survival of
HH patients was the same as age- and sex-matched controls without the disease if
treatment was initiated before the development of cirrhosis or diabetes (26).

The

treatment for hemochromatosis, therapeutic phlebotomy, has been used medically for
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centuries and for hemochromatosis since the 1950s.

Initially 500 mL of blood are

removed per week until ferritin is less than 10-20 ug/L.

Then patients undergo 4-8

phlebotomies per year for life to maintain ferritin levels less than 50 ug/L (27).

The

therapy is safe, economical, and effective.
Secondary hemochromatosis is most often seen in the context of those diseases
requiring therapeutic blood transfusions, like thalassemia and the hemoglobinopathies.
Patients with these diseases accumulate excess iron in two ways.
erythropoesis stimulates increased intestinal iron absorption.

First, ineffective

The second and more

significant burden is the weekly transfusions that cause a condition known as transfusion
siderosis.

A single unit of blood contains between 200-250 mg of iron—a staggering

amount compared to the normal 1 mg per day that is excreted. This iron, being derived
from senescent erythrocytes, is first cleared by reticuloendothelial macrophages. Much
of the iron is ultimately recycled to transferrin and delivered to parenchymal cells,
producing the same pattern of overload as hereditary hemochromatosis.

Myocardial

siderosis is the most important cause of mortality in sub-optimally treated transfusional
overload, possibly because of the rapidity of iron loading (28).
Therapeutic phlebotomy is precluded by the nature of the primary disease. Iron
chelation therapy with desferroxamine has been used effectively since the early 1960s.
Treatment involves continuous subcutaneous or intravenous delivery by portable pumps.
Such a schedule is necessary to limit hepatic iron load to less than 15 mg per gram of
liver, dry weight (29). Although desferroxamine is relatively non-toxic, excessive doses
can cause skeletal growth abnormalities and sensorineural hearing loss (30). The major
shortcomings of DFO therapy, however, are the high cost and the inconvenient and
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uncomfortable mode of delivery.

Oral chelators such as deferiprone have been

developed, but are not universally effective and have complications (17).
There is clearly room for therapeutic intervention in the management of iron
overload diseases.

A convenient, non-toxic, inexpensive therapy would be a welcome

replacement for desferroxamine in cases of transfusional overload.

And although

phlebotomy is safe and expedient for patients with hemochromatosis, there are hints that
a steady, rather than intermittent therapy might be more appropriate. Clinical data and
cellular iron metabolism support the notion of continuous therapy. While long term DFO
treatment removes non-transferrin iron from the blood, on cessation of therapy it
reappears rapidly, necessitating continuous therapy (31).

There is also a physiologic

advantage to removing cellular iron before it becomes durably bound up in ferritin or
hemosiderin particles.

Ferritin most efficiently releases iron when it is only partially

bound with iron (14).

Studies with Mossbauer spectroscopy support this feature by

demonstrating that most iron mobilized by DFO is derived from small (< 0.3 nm),
recently acquired iron particles.

Larger particles, such as the iron core of ferritin

molecules are conversely unavailable for DFO chelation (32).

Cellular Iron Metabolism

An understanding of the regulation of cellular iron metabolism helps elucidate the
mechanisms of systemic iron overload. This knowledge is also critical in any therapeutic
attempt to manipulate or else circumvent the pathologic patterns of parenchymal iron
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accumulation. The homeostasis achieved in iron metabolism involves the participation of
different transporters and storage molecules. Iron is deposited in two forms in tissue—ferritin and hemosiderin.

Ferritin is the major storage protein for iron in the body;

normally twice as abundant as hemosiderin. It can both accept iron in states of excess
and release it in times of erythropoetic demand. This flux occurs most efficiently with
iron in its reduced, ferrous state (33). Once in ferritin’s protein core, however, the iron is
oxidized and maintained in the ferric form. A single molecule of ferritin can store up
anywhere from 2500 to 4500 atoms of ferric iron in this manner (34, 35). When ferritin
becomes saturated with iron, its protein shell is partially degraded by lysosomal proteases
to yield hemosiderin.

Hemosiderin is an insoluble, ill-defined aggregate of iron oxide

with organic constituents. It is up to 40% iron by mass. Compared to ferritin, it is a more
durable sink for iron (14). This explains the prevalence of hemosiderin deposits in states
of iron overload.

As total tissue iron levels increase, so does the proportion of

hemosiderin to ferritin. In liver biopsies of iron-overloaded patients, hemosiderin levels
were 100-fold and ferritin only 10-fold above normal (36).
There are two major forms of iron transport in the body—one mediated by
transferrin and one that is transferrin-independent.

The function and regulation of the

transferrin-mediated pathway is well characterized.

Mammals evolved transferrin as a

necessary solution to the evolutionary problem presented by ferric iron—a form which
lacks both solubility and bioavailability. By transporting iron as a soluble diferric chelate
between body compartments, transferrin presents iron in a form amenable to cellular
uptake and responds to cellular iron needs. Uptake of transferrin bound iron occurs via
receptor-mediated endocytosis.

Upon binding to its high affinity cell surface receptor.
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present on nearly all cell types, transferrin dimerizes. The transferrin-receptor complex is
internalized. Following acidification of the endosome, the transferrin receptor (TfR) is
recycled to the cell surface and iron is released into three cytosolic pools. It is utilized in
heme proteins and metabolic enzymes, sequestered in ferritin, or enters a transient
regulatory pool that controls iron levels in the cell (37, 38).
The regulatory form of iron maintains cellular iron balance by controlling the
translation of ferritin, transferrin receptor (37, 13), and divalent metal cation transporter
DMT1 mRNAs (39). The system is an example of post-transcriptional control, which
allows a rapid and sensitive response to cellular needs for iron. When iron enters a cell it
is bound by cytosolic iron binding proteins. This iron-protein complex affects translation
by interacting with regions on the mRNA of both the TfR and ferritin called iron
responsive elements (IREs). When iron binds the protein, the protein is released from the
IRE.

Release of the binding protein from the 3’ IRE in the TfR mRNA destabilizes

mRNA stability decreasing translation of the message into TfR protein and thus reducing
transferrin-mediated iron uptake. Alternatively, release of the binding protein from the
IRE in the 5’ end of ferritin mRNA allows its translation, increasing synthesis of ferritin
and intracellular iron storage (37, 40).
The type of regulation represented by the transferrin receptor ensures cellular iron
homeostasis.

Ward et al. was among the first to demonstrate that TfR number was

regulated by intracellular iron content rather than ligand binding—a mechanism akin to
LDL receptor regulation.

Preincubation of fibroblasts with ferric ammonium citrate

reduced the number TfRs per cell, whereas saturating levels of Tf(Fe)2 or apo-transferrin
had minimal effect on TfR expression (41).
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Another mechanism of iron uptake, a non-transferrin-bound iron uptake system,
was first recognized by Wheby and Crosby in 1963 and continues to be characterized
(42) .

Its function and regulation varies widely from that of transferrin.

In fact, it has

been shown that iron uptake by this mechanism is entirely independent of transferrin.
Sturrock et al demonstrated iron uptake in HeLa cells in the presence of inhibitors of
receptor-mediated endocytosis and at a pH of 5.5 at which transferrin binds iron poorly
(43) .

It is thought that the uptake occurs between low molecular weight iron-organic

anion chelates by a membrane-based system present on a variety of cultured cell types
(44) .

The iron substrate is believed to be the more soluble ferrous form, possibly

following cell surface reduction by a mammalian ferrireductase similar to that in bacteria
and fungi (45).

Using such iron chelates (y,Fe-nitriloacetate, y)Fe-citrate, and 59Fe-

Tricine ascorbate), Sturrock et al demonstrated that uptake in HeLa cells was time- and
concentration-dependent, saturable, and subject to competitive inhibition by other
divalent metals. In K562 cells metals such as Co, Ni, and Mn permeated at rates similar
to iron (46). These results suggested that the transport mechanism consisted of a carrier
for several divalent metals including iron.
It is apparent from studies on the regulation of the non-transferrin system that its
purpose is widely divergent from that of the transferrin pathway.

Some transferrin

independent pathways are unique in that they do not necessarily exist to fulfill cellular
iron needs. In cultured HeLa cells and fibroblasts, Kaplan et al produced iron uptake that
was independent of changes in cell growth rate, induction of DNA synthesis and cell
division, or cellular iron needs. What did increase transport activity, however, was mere
exposure of the cells to either ferrous or ferric iron. Kaplan found that pre-incubation of
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cultured cell lines with inorganic iron (ferric citrate) actually enhanced uptake of
subsequent radioactive iron (44).

Based on these results it was proposed that

extracellular iron was capable of catalizing the appearance and activity of the membrane
iron transporters responsible for its uptake. Parkes et al similarly demonstrated a positive
correlation between cellular iron content in cultured rat myocardiocytes and the rate of
non-transferrin-bound iron uptake (47). As it was then proposed, the function of this iron
transport pathway seems to be the clearance of non-Tf iron from plasma—a physiologic
‘salvage pathway.’
A candidate iron transporter gene has recently been identified. The gene, initially
called Nramp2, belongs to

a family of ubiquitous trans-membrane transporters

purportedly involved in dietary iron absorption. Nramp2 was found to co-segregate with
a phenotype of homozygous mk/mk mice that have microcytic, hypochromic anemia due
to severe defects in intestinal iron absorption (48).

The relationship between Nramp2,

now called DMT1 (divalent metal transporter 1), and the defective HFE gene in
hereditary hemochromatosis is poorly characterized.

Whatever the primary defect in

intestinal iron transport, a recent study on regulation of DMT1 expression makes it
doubtful that the same defect is responsible for the parenchymal overload
hemochromatosis and transfusional iron overload.

in

In HFE knockout mice, hepatic

DMT1 expression was not elevated despite increased expression of this transporter in
duodenal cells (24). Also, it appears that DMT1 expression is appropriately regulated by
cellular iron status and therefore would not continue iron transport into iron-loaded cells.
Gunshin et al found that in iron deficient mice, DMT1 expression in the duodenum was
suitably increased (49).
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Iron Overload States
Clearly in states of iron overload, though, iron enters parenchymal cells in
amounts sufficient to cause multi-organ failure.

Liver iron content in patients with

hereditary hemochromatosis is between 50-100X normal. The 20-40 g of total body iron
accumulated

in

patients

approximately 3 g (15).

with

hemochromatosis

far

exceeds

normal

levels

of

Iron content in the liver of a double organ transplant

hemochromatotic was 28.1 mg iron/gm dry weight (47). Normal males, in comparison,
have 0.17 mg iron/gm dry weight (50). Untreated thalassemia patients accumulate toxic
amounts of iron by age ten and lethal amounts by adolescence (51). Two questions arise,
then, when considering parenchymal iron burden in iron overload diseases. What is the
mechanism of transport into parenchymal cells? And, is it physiologic or does it reflect a
defect in regulation similar to the primary defect present in intestinal iron absorption?
It was initially speculated that a defect in transferrin receptor was responsible for
the inappropriate iron uptake by parenchymal cells in states of iron overload.

Gatter’s

discovery that the selective organ distribution of TfR expression paralleled that of tissue
damage in hereditary hemochromatosis, lead to his proposition that high levels of
transferrin receptor expression might be responsible for increased iron uptake in the liver
and pancreas (54). Further studies on TfR expression revealed that this association was
not causal. Ward et al investigated characteristics of TfR regulation in patients with
hereditary hemochromatosis to uncover whether any disregulation of this receptor was
responsible for the massive tissue iron accumulation.

Using cultured fibroblasts and

mitogen-stimulated lymphs from HH patients, it was shown that transferrin receptor
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number and affinity, as well as the ability to down-regulate was similar to that in cells
from normal controls (53).
Despite the appropriate down-regulation of the transferrin receptor, parenchymal
iron overload still occurs. It appears that non-transferrin iron uptake, which actually upregulates in conditions of cellular iron loading, is the operative pathway. Melanoma cells
preincubated with ferric ammonium citrate have shown increased non-receptor mediated
uptake of iron from transferrin and a decrease in receptor-mediated uptake (54).
Secondary to the saturation of transferrin, high levels of non-transferrin iron are present
in the plasma of hemochromatotics. Whereas normals have between 0.6-1 uM non¬
transferrin bound iron, levels approach 5-15 uM in hereditary hemochromatosis (55).
Hepatic clearance of this form of iron appears to be both efficient and rapid, suggesting
that non-transferrin bound iron could be the direct cause of toxic iron burden in the liver.
Brissot et al, using a rat liver perfusion system demonstrated that hepatic uptake of luM
non-transferrin 55Fe from human serum had a single-pass extraction efficiency of 5885%. The Km of uptake, at 14-20 uM iron, interestingly approximated the levels of non¬
transferrin bound iron in states of overload (56). Another study in Tf iron-saturated rats
and found that more than 80% of subsequently injected radiolabelled iron was cleared
from the plasma by 30 seconds.

PAGE analysis revealed that this iron was in a non¬

transferrin associated form (57). These results are compatible with the knowledge that
intestinally absorbed iron in HH patients is efficiently removed by the liver before
entering systemic circulation (58).
The predicament of parenchymal iron loading is clear.
regulation

of transferrin-mediated

pathways

is

insufficient

Appropriate downto

avoid

overload.
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Simultaneously, the uptake of non-transferrin bound iron is functioning maximally,
causing a great deal of cellular toxicity.

Unless plasma iron levels are reduced this

pattern will continue unchecked. How then can excess iron be eliminated from the body?
Absorption may not be the best site for effecting change because the exact mechanism of
normal and abnormal iron uptake is unclear.

Chelators can increase urinary iron

excretion, but the inconveniences of this mode of therapy have previously been
illustrated. The epidermis, which is already responsible for nearly 25% of daily body iron
excretion, has not yet been considered a site for therapeutic intervention. Interestingly,
though, this route of iron elimination is already slightly enhanced in patients with HH.
Increased amounts of iron are present in the basal epidermal layer of patients with
hemochromatosis (59). Also, measures of skin iron content by X-ray spectrometry have
been shown to correlate well with body iron stores (60).

These findings suggest that

excessive iron can be delivered to keratinocytes and that keratinocytes are capable of
augmenting their iron stores. Therefore, the goal of artificially enhancing epidermal iron
losses is consistent with a pre-existing physiologic response.

Iron in the epidermis
Information about iron in the epidermis is somewhat limited. The specificity of
epidermal iron distribution most likely reflects the selective expression of the transferrin
receptor in the basal epidermis (61). Indeed, proton microprobe analysis reveals that iron
is more abundant in the basal layers of the epidermis (62).

Dermally injected 59Fe

demonstrates a predominance of iron in the basal layer of the stratum malpiphii that
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decreased toward the stratum granulosum (4). Various methods have been employed to
measure epidermal iron content.

Estimates range from approximately 0.03 to 0.24 mg

iron/gram dry weight in normal skin (2, 63). In normal necropsy specimens, the total iron
content of epidermal skin was determined to be 22.5 ± 17.8 mg (64); a small amount
relative to the liver iron stores of 2.2 mg per gram (Mayo Labs upper limit of normal).
There are two potential routes for epidermal iron loss—desquamation and
perspiration.

Initially, there was much controversy about the relative contribution of

sweat to body iron loss.

Numerous studies concluded that the amount of iron lost in

sweat approached several mg per day (65, 66, 67). Sweating was even implicated as an
etiologic factor in iron deficiency in tropical climates (68). Such diverse results represent
the inherent difficulties of measuring iron loss because of the small quantities measured,
methodological error, and environmental contamination with iron (69).

Present

understanding of body iron balance also makes the results of those studies dubious at
best. A convincing study by Green et al concluded that perspiration was an insignificant
source of total body iron loss. “Seattle whites” at desk jobs lost 0.95 mg total iron per
day compared to steam laundry workers in Durban, South Africa who, despite conditions
of high temperature and humidity, still lost only 1.02 mg iron per day (64).

A more

recent estimate of cell-free sweat iron loss was calculated to be approximately 0.01
mg/day—a trivial portion of the 1-2 mg total lost daily (7).
It is now appreciated that the major source of epidermal iron loss results from
desquamation.

These losses actually represent a significant fraction, about 20-25%, of

daily total iron losses, making the skin an important participant in iron homeostasis.
Weintraub was one of the first to propose that the skin ‘acts as an active excretory organ
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for iron.’

He found that whole body iron loss following intravenous injection of ~9Fe

citrate was 3-fold greater than could be accounted for by urine and stool losses alone.
The remainder, he proposed, was lost through desquamation (4). The amount of skin iron
loss has been estimated by calculations based on various parameters, including epidermal
turnover time and skin iron content. Cellular turnover of the skin—the time it takes for a
basal cell to traverse the epidermis and desquamate—is between 26-28 days. In healthy
individuals, up to 1.0 g of normal epidermis is desquamated per day (70, 71).

From a

recent measurement of skin iron content, 0.24 mg iron/gm dry weight (63), then, one
could predict that 0.24 mg iron would be lost daily via desquamation. Using estimates of
total epidermal iron content of between 3-14 mg and as 22.5+/-17.8 mg, Bothwell
hypothesized that daily skin iron loss ranged from 0.2 mg to 1.2 mg (15).
An alternative approach to estimating desquamative iron losses is to assume that
daily skin iron loss represents a steady state and that the amount of iron entering the skin
equals the amount exiting. Green et al intravenously injected >9Fe in to patients 16-24
hours before they were scheduled to undergo operations in which skin would be removed.
They found that at normal transferrin saturations, skin iron uptake from plasma was
between 0.2 and 0.3 mg per day (64).
In disrupted metabolic states skin iron uptake and losses diverge from normal.
One can imagine that the primary ways by which to increase skin iron loss would be
either to increase cellular turnover time or to increase skin iron content. Two diseases—
psoriasis

and

hemochromatosis—

reproduce

these

conditions,

respectively.

In

hyperproliferative states like psoriasis where turnover time is increased 4-fold, skin iron
losses increase, possibly contributing to iron deficiency in these patients (72).

The
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question of iron levels in the skin of hemochromatotics has not been satisfactorily
resolved. It is known that the ‘bronze’ skin discoloration is due to the accumulation of
melanin rather than epidermal iron or hemosiderin (73).

Pathologic iron deposition,

however, does occur in the skin, mainly in the basal layers (74). Some studies, though,
do imply that there is an augmentation of epidermal iron uptake in situations of iron
overload.

Green et al found that skin iron uptake increased linearly with a rise in

transferrin saturation—from the normal 0.2-0.3 mg/day to 0.6-0.7 mg/day (64).

In

another study, intravenous radioiron injections produced positive Prussian blue staining
of the epidermis, indicating that intracellular iron existed in excess of physiologic cellular
needs (4). The correlation of skin iron concentration and parenchymal tissue iron in iron
overload has already been mentioned. One would assume, then, that HH individuals have
higher than normal skin iron losses.

Despite the belief that no excretory mechanism

exists for iron, data on iron overload patients suggests that late in the disease a balance
between absorption and excretion is approached.

Daily iron losses increase from the

normal 1 mg/day to 1.5 mg/day in these patients, particularly due to increasing skin iron
losses (15). This indicates that a vector of transfer exists between plasma and skin and
adds support to a design whereby skin could be exploited as an organ of iron excretion.
Are there ways to further shift the burden of iron load to keratinocytes? In most if
not all cell types the transferrin-mediated uptake is down regulated in iron overload.
Non-transferrin bound iron uptake is already optimized and still not enough iron is lost
through the skin. Recently, a candidate for an alternate route of iron loading has been
identified. The discovery, as it turns out, was serendipitous. A group of hematologists,
aware that iron transport is calcium sensitive, were studying the effects of calcium
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channel blockers on iron uptake in erythroid cells.

Specifically they were looking for

inhibition of iron uptake in the presence of calcium channel blockers.

The surprising

result was a 3 to 4 fold increase in uptake in the nifedipine-exposed cells. The effect only
occurred when the nifedipine was photodegraded;
ineffectual.

light-shielded nifedipine was

They localized activity to the major photodegradation product of

nifedipine—a fully aromatic nitrosopyridipine derivative.

The nitroso-derivative

produced a temperature sensitive, bi-directional change in uptake of non-transferrin iron
only; no effects were seen with transferrin bound iron.

Iron uptake by the nitroso-

derivative occurred at a different pH optimum and in the presence of known inhibitors
suggesting that these effects were independent of the established mechanisms of non-Tf
iron transport.

It was proposed that the PDN derivative represented a ‘mobile iron

ionophore’ (75).
The effects of photodegraded nifedipine are not limited to iron transport. Luttrop
et al were attempting to enhance gallium uptake in tumor cells for improved radiographic
imaging. Because gallium is an iron analogue, they predicted that PDN might similarly
mediate its cellular uptake. Using 25 uM photodegraded nifedipine, they achieved up to
a 1000-fold increase in Ga-67 uptake. The effect was independent of transferrin and its
receptor. As PDN did not alter the lipophylicity of Ga-67 citrate, they concluded that the
mechanism of PDN-mediated gallium uptake does not involve the formation of a
lipophyllic complex or carrier that diffuses across membranes (76).

This implies a

mechanism independent of DMT 1—a known iron carrier.
Nifedipine is the prototype of the dihydropyridine class of calcium channel
antagonists. It is used commonly to treat hypertension and angina pectoris. Nifedipine’s
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photodegradable properties have been known for a long time.

In 1931 a qualitiative

observation was made that a specific class of dihyropyridines was sensitive to light.
Another early paper cites the 366 mu wave length which catalyzes a reduction of the
nitro- group to produce an aromatizing dehydrogenation (77).
yield different reaction products.
wYrophenylpyridine

product.

Different light sources

Exposure of nifedipine to UV light produces a
Daylight

results

in

the

predominance

of

a

mYrosophenylpyridine product (78).
The above reactions proceed quickly because dihydropyridines are remarkably lightsensitive, with half lives in the range of minutes (79).

Photodegradation products of

nifedipine have even been isolated from hospital prescriptions (80). This characteristic
makes nifedipine a potentially safe therapeutic agent. In the photodegraded form it has
only minimal calcium channel blocking activity suggesting that the pharmacological
effects of nifedipine are different from those of its derivatives.

Several recent studies

have documented that nifedipine-induced reduction of calcium current amplitude can be
reversed within milliseconds after a brief light flash (81, 82).
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Hypothesis

The founding idea of this project is that the normal process of epidermal
desquamation can be harnessed to eliminate toxic chemicals from the body.

The

presumption is that keratinocytes are capable of accumulating and retaining iron and that
this iron load would be lost from the body by desquamation.
Our hypothesis is that photodegraded nifedipine represents an effective way to
pharmacologically increase the iron content of human keratinocytes.

Iron uptake and

total iron content in keratinocytes exposed to PDN in vitro will be measured.

We will

investigate the effect of time of PDN exposure, dose of iron, and state of differentiation
on the characteristics of uptake.
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Methods

Cell Culture
Human neonatal foreskins were obtained from the Yale Children’s Hospital.
Tissue was washed twice and incubated overnight at 4°C in dispase. The following day,
the tissue was removed from the incubator, the epidermis was peeled from dermis and
then incubated at room temperature for 10 minutes. The epidermis was incubated at 37°C
for 15 minutes in 3 mL of trypsin + EDTA. 4 mL STI was added to stop the reaction.
Cells

were

counted,

approximately 5 x 106.

centrifuged,

then

resuspended

in

cMCDB

and

Cells were split after reaching 50-70% confluence.

seeded

at

We used

keratinocytes at 3rd, 4th, or 5th passage when grown to a near confluent monolayer in 6well plates. (83, 84)

Photodegradation of Nifedipine:
Nifedipine (Sigma chemical Co., St. Louis, MO) was dissolved in 1 mL ethanol
for a concentration of 10 mmol/L. The sample was shielded from light and stored at -4°C
until intended photodegradation was conducted (76). To photodegrade the nifedipine, the
sample was exposed to direct outdoor daylight in a clear 1.5 ml polypropylene microfuge
tube for exactly one hour. Adequacy of photodegradation was confirmed by thin-layer
chromatography (TLC) on silica gel using a hexane:chloroform:acetone solvent in a
50:30:20 ratio (75). The TLC was then photographed on a UV light box using Polaroid
film.
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Preparation of Iron Incubation Solution
An incubation medium with a 15 uM concentration of iron was used in all
experiments unless otherwise stated.

1 uM of the above medium was radioactive iron,

?9FeCl3 (Dupont NEN, Fe-59 chloride).

The other 14 uM was made up with 56FeCl3

(Fisher Scientific Co., Fair Lawn, N.J.).

The appropriate volumes of Fe-59 and Fe-56

were combined in a 15 mL centrifuge tube. A molar excess of Tricine ascorbate (10 mM
tricine, 0.3 mM ascorbate) made in Hank’s balanced salt solution (HBSS) was added to
the iron.

Tricine was selected as a nonmetabolized amino acid that binds to, and

effectively solubilizes, both ferrous and ferric iron (56).
coordinator of ferrous iron in plasma (85).

Ascorbate is an important

The HBSS, pH 7.2-7.4, contained 1 mM

CaCb, 1 mM MgCh and 3.7 g/L NaHCCL (76). The iron/tricine ascorbate solution and a
separate 6 ml of HBSS in a 15 mL centrifuge tube was allowed to equilibrate uncapped at
37°C in a 4% CO2 incubator for 30 minutes prior to use.

59Fe Uptake
The following was adapted from Luttrop et al (76). After growth of keratinocytes
in 6-well plates to near confluence, monolayers were washed and then preincubated for 2
hours at 37°C in 2 ml serum-free Dulbecco’s Modified Eagle medium (DMEM) (GIBCO
Laboratories, Grand Island, NY) to deplete cells of transferrin. At the end of 2 hours, the
preincubation medium was removed and replaced with 1 mL per well of incubation
solution containing 15 uM iron (76). The incubation solution for the experimental group
contained
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uM photodegraded nifedipine

(PDN);

controls received

an

equal
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concentration of ethanol.

Cells were incubated in a 4% CO2 incubator at 37°C for

varying intervals of time, depending on the experiment.

Cell Harvest
The following protocol was adapted from Luttrop et al (76).
incubation with 59Fe, flasks were immediately placed on ice.

Following

The incubation medium

was removed by aspiration with a Pasteur pipette attached to water suction.

Cell

monolayers were washed once with ice-cold calcium magnesium free phosphate-buffered
saline (CMF PBS), then twice with CMF PBS prewarmed to 37°C.

CMF PBS was

removed. To obtain a cell suspension, monolayers were trypsinized with 700 uL 0.05%
trypsin + EDTA at 37°C for 3-4 minutes.

The cells and trypsin were collected and

carefully layered over a 200 uL column of dibutylphthalate:paraffin oil (8.5:1.5) in 1.5
mL tubes. To separate the cells from contaminating extracellular radioactivity, the tubes
were centrifuged at 11,000 rpms for 2 minutes. The supernatant was then aspirated with
a Pasteur pipette attached to water suction. Using a microfuge tube clipper, the bottom of
the microfuge tube containing the cell pellet was clipped into a counting vial containing
900 uL solution of 200 mmol/L NaOH and 1% sodium dodecyl sulfate. The amount of
radioactivity in the cell pellets was determined by gamma counting (CompuGamma
1282, PerkinEhner Wallac, Inc.)

Protein Assay
Protein assays of the solubilized cell samples were performed by formation of the
cuprous bicinchoninic acid complex, and quantified according to absorption on a
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spectrophotometric microtiter plate reader (Dynatech Laboratories).

The method and

reagents used are supplied in a kit (Pierce Chemical Co., Rockford, IL). Bovine serum
albumin was used as a standard of reference.

Stratified Cell Cultures
Human keratinocytes were seeded into 6-well plates (9 cm /well) and grown in
cMCDB medium until confluent. At confluence, the medium was changed to DMEM/
F12 + 10% fetal calf serum (FCS) to allow cells to stratify. This was a modification of
the method in Zhou et al (83).

One week after the medium change, the stratified cell

layers were separated from the underlying basal cells as follows.

The DMEM growth

medium was aspirated and cells were washed twice with CMFPBS.

Cells were then

incubated at 37°C in a CO2 incubator for 10 minutes in 2 ml of versene (GIBCO, Grand
Island, NY). Immediately following incubation, the stratified cell layer was gently
separated from the basal layer with forceps (83). The sheet of stratified cells was then
washed twice in a separate dish with PBS + 0.5 mM CaCF- to saturate any remaining
versene. Each stratified layer was then laid in the well of a 6-well plate containing 2 ml
of DMEM/F12 + 10% FCS and incubated at 37°C overnight.

The versene left in the

wells containing the intact basal cells was aspirated. These basal cells were washed 3X
with PBS + 0.5 mM CaCf then incubated overnight at 37°C in 2 mL cMCDB to prevent
differentiation.
On the day of the experiment growth medium was removed. The stratified, freefloating suprabasal, and basal cells layers were preincubated in regular DMEM for 2
hours. Iron uptake studies with 15 uM iron, +/- 25 uM PDN were conducted at 37°C for
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20 min as previously described. The collection of the cells differed slightly. Basal cells
were trypsinized in 0.05% T+E for 1 min, spun through oil, and gamma counted.
Stratified cell layers were gently scraped from the wells with a rubber policeman and
washed in CMF PBS three times.

The suprabasal cells were removed intact to vials

containing 900 ul of NaOH/SDS. Gamma counting and protein assay were performed on
these two cell types.

Statistical Methods
In all experiments, standard deviation was calculated for each experimental and
control group. This variance is represented as vertical error bars on all displayed graphs.
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Results

Thin-layer chromatography
A 10 mM solution of nifedipine in absolute ethanol was divided into 3 equal
aliquots in 1.5 ml plastic microfuge tubes.

One sample was shielded from light.

The

other two were exposed to outdoor daylight for time intervals of 30 and 60 minutes.
These solutions were run on a silica gel using a hexane:chloroform:acetone solvent in a
50:30:20 ratio (75). Thin layer chromatography showed the disappearance of the original
substance and the appearance of a major photodegradation product with increasing
duration of light exposure.

This product has previously been identified as a fully

aromatic nitrosopyridine derivative of nifedipine (75,76).

It is the major product of

daylight-induced degradation of nifedipine (78). Other minor degradation products have
also been identified but could not be detected here because of the insensitivity of the
employed method.
product is 0.76.

The RF value of nifedipine is 0.68; that of the photodegradation
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Photodegraded nifedipine (Rf = 0.76)

-apfc

Nifedipine (Rf = 0.68)
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Fig 2. Thin Layer Chromatography of nifedipine exposed to daylight. A 10 mM
solution of nifedipine was exposed to outdoor daylight for variable intervals of time and
examined by thin-layer chromatography. This experiment is representative of
experiments performed three times.

Iron Uptake
The effect of photodegraded nifedipine on free iron uptake in erythroid cells (75)
and of gallium uptake in CHO and mouse 3T3 lines (76) has already been documented.
In these cell types degree of metal uptake varied considerably.

Erythroid cells

demonstrated approximately 3 to 4-fold increase in iron uptake when exposed to PDN,
whereas CHO and mouse 3T3 lines boasted gallium uptake of 1000-fold.

We

demonstrated that PDN is capable of stimulating iron uptake in normal human
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keratinocytes. After a 30 minute incubation with 15 uM solution of 59Fe in the presence
of 25 uM PDN, proliferating monolayers of keratinocytes produced an 18-fold increase in
iron uptake. This was significantly different from non-transferrin bound iron uptake in
control cells incubated in equivalent concentrations of ethanol.

The experiment was

repeated twice.
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Fig 3. Iron uptake in basal keratinocytes exposed to photodegraded nifedipine.
Normal human keratinocytes were treated for 30 minutes with 25 uM PDN or ethanol and
15 uM 59Fe, as described in methods. The PDN-exposed group demonstrated a 20-fold
increase in iron uptake versus controls. Results are mean ± S.D. of 6 samples. This data
was combined from two identical experiments.

Time Course of Iron Uptake
There is a time-dependent cellular uptake of iron with exposure to photodegraded
nifedipine. Preconfluent proliferating keratinocytes were incubated in 15 uM iron with or
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without 25 uM PDN and harvested at 1, 5, 15, 30, 60, 120 and 180 minutes.
occurred rapidly.

Uptake

By one minute, keratinocytes incubated in the presence of PDN

demonstrated a 6.7-fold increase in iron uptake above controls.

Longer periods of

incubation revealed a linear increase in iron uptake that eventually plateaued.
plateau was reached between 60-120 minutes.

The

The most significant increase in PDN-

mediated iron uptake above that in controls (presumably non-transferrin iron uptake)
occurred at 30 minutes where uptake was approximately 87-fold greater than controls.

control
PDN

minutes

Fig 4. Time course of iron uptake in PDN and control keratinocytes. Keratinocyte
monolayers were incubated at 37°C with 15 uM Fe in the presence or absence of 25 uM
PDN. Each data point represents the mean of three samples ± S.D. This experiment was
repeated three times.
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Dose Response
Preconfluent monolayers of keratinocytes were incubated for 20 minutes at 37°C
with either 1 uM, 5 uM, 15 uM, 20 uM, or 30 uM concentrations of iron. 25 uM PDN
was added to the incubation solution in experimental groups.

Controls received equal

concentration of ethanol. Cells were harvested and iron uptake as represented by umole
iron/cell was calculated from measured cpm values.

There is a clear dose-response

relationship between iron concentration in the incubation medium and cellular iron
uptake. At concentrations as low as 1 uM, significant uptake of iron was evident in the
PDN-exposed cells. These cells took up 77-fold more iron than controls. Though the
greatest amount of uptake occurred at the highest iron concentration tested (30 uM), the
largest difference between PDN and control cells occurred between 1-15 uM and peaked
at 5 uM. At this point experimental groups demonstrated a 102-fold difference in uptake
from controls.
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Fig 5. Response of iron dose on uptake in keratinocytes. Preconfluent monolayers of
keratinocytes were exposed to varying concentrations of 59Fe for 20 minutes at 37°C.
Each data point represents the mean of 3 samples ± S.D. This experiment is
representative of experiments performed twice.

Effect of pH on uptake in stratified cells
The effect of PDN on iron uptake raises two possibilities. Either PDN augments
the existing non-transferrin pathway or it functions independently.

Savigni et al

demonstrated that PDN increased iron uptake in the presence of potent inhibitors of non¬
transferrin uptake. They also found that PDN and non-transferrin mediated iron uptake in
erythroid cells was optimal at different pH levels (75). We wished to examine whether a
similar disparity occurred in keratinocytes. An isotonic incubation solution made of 20
mM PIPES buffer in 150 mM NaCl was titrated with 1 normal NaOH to give solutions of
pH 6.1, pH 6.5, pH 7.0, and pH 7.5. Stratified keratinocytes were incubated with 15 uM
iron with or without 25 uM PDN in the varied pH incubation solutions for 20 minutes.
Iron uptake in the PDN exposed cells was markedly increased over that of controls at all
pH values tested.

There is a clear difference in pH optimum between the PDN and
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control groups.

PDN-mediated iron uptake occurred maximally at pH 7.5 or greater.

Alternately, iron uptake by keratinocytes in the absence of PDN peaked distinctly at pH
6.5.

Fig. 6. Effect of pH on iron uptake in keratinocytes. Cells were incubated with 15 uM
Fe for 20 minutes at 37°C in isotonic NaCl buffered at the indicated pH values with 20
mM PIPES. Experimental cells had 25 uM PDN added to the medium. Each data point
is the mean of 3 samples ± S.D. Note the clear difference in peak iron uptake between
PDN-exposed cells and controls. This experiment was performed once.

Iron Uptake in stratified cell layers: Stratified vs. Basal vs. Suprabasal
We sought to uncover whether differentiation state would affect cellular iron
uptake.

As described in methods, we conducted iron uptake experiments in basal,

suprabasal and stratified cell layers. Cells were incubated at 37°C for 20 minutes in 15
uM iron either with 25 uM PDN (experimental group) or 25 uM ethanol (controls).

□
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There was significantly increased iron uptake in all PDN-exposed cells.

The greatest

amount of uptake in cpm/ug total protein occurred in the stratified cells. In these cells, a
16.4-fold difference in iron uptake over controls is apparent. PDN-incubated suprabasal
cells did not show as great a difference, 3.7-fold, compared to controls.

n control
□PDN

Fig. 7. Effect of cellular differentiation on iron uptake. Intact, stratified keratinocyte
cell layers (Strat 1) and detached suprabasal, stratified cell layers (Supra 1) were
incubated with 15 uM Fe for 20 minutes at 37°C in the presence of absence of 25 uM
PDN. The results reveal a greater difference in uptake between PDN-exposed cells and
controls in the intact, stratified group. Each bar represents the mean of 3 samples ± S.D.
This experiment was performed twice.

Iron Accumulation
The experiments studying iron uptake demonstrate that uptake occurred during a
single, brief exposure to PDN. We were interested to see whether repeated exposures of
cells to iron in the presence of PDN would actually alter cellular iron content. Twenty
two x 60 mm dishes of normal human keratinocytes were grown to confluence and then
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allowed to stratify in DMEM/F12 + 10% FCS for one week (84).

On the first day of

experiments, 6 dishes were sacrificed for time zero protein assay and iron content. The
remaining 16 dishes were incubated at 37°C for one hour with 20 uM 59Fe. In half of the
dishes, the incubation solution contained 25 uM PDN, the others consisted of 25 uM
ethanol.

At the end of the 1 hour incubation, cells were washed, replaced in growth

medium (cMCDB + 1.4 mM Ca+2), and returned to the incubator. This procedure was
repeated daily for a total of five days.

After the final iron incubation, cellular iron

content was measured by inductively coupled plasma mass spectrometry.

PDN-treated

cells showed a 3-fold increase in total iron content. Iron content in these cells averaged
403.4 ± 22.4 ug iron/g dry weight compared to controls whose average iron content was
147.6 ± 10.7 ug iron/g dry weight. Jing Zhou, Ph.D. performed this experiment.

Fig. 8. Accumulation of iron in keratinocytes exposed to PDN. Stratified keratinocyte
cell layers were incubated with 20 uM Fe with or without 25 uM PDN for 1 hour at 37°C.
This procedure was repeated daily for a total of five days. Cells were sent for analysis of
iron content. Each bar represents the mean of five samples ± S.D.
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Iron Retention
Keratinocytes also demonstrated the ability to retain iron after loading in the
presence of PDN. Confluent, stratified keratinocytes were treated for 1 hour in 20 uM
Fe-tricine ascorbate with or without 25 uM PDN.

Cells were washed and returned to

standard medium (DMEM/F-12 with 10% FCS) for 24 hours.

This procedure was

repeated daily on 4 successive days. Epithelia were maintained in standard medium an
additional 4 days then sent for analysis of iron content by inductively coupled plasma
mass spectrometry. PDN-treated samples showed a 3-fold increase in total iron content
that persisted through the washout period. This experiment was performed by Jing Zhou,
Ph.D.

Fig. 9. Retention of iron after washout in keratinocytes exposed to photodegraded
nifedipine. On days 0-4 cultures were pulsed once daily with iron (20 uM) and PDN (25
uM) or ethanol (controls). Iron content was measured as described in methods.
Accumulated iron persisted 4 days beyond the last PDN treatment.
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Discussion
Our results demonstrate the powerful effect of PDN in stimulating non-transferrin
bound iron uptake by keratinocytes in vitro. The effect of PDN on free iron uptake in
erythroid cells (75) and of gallium uptake in CHO and mouse 3T3 lines (76) has already
been documented. The light dependence of the PDN-mediated iron uptake has already
been shown by Savigni and was not tested here.
stimulate Fe (II) uptake in erythroid cells (75).

Light-protected nifedipine does not
Kathryn Morton has crystallized the

nitroso-derivative (nitrosopine) and shown it to be the active derivative (Morton, personal
communication).
We found that the magnitude of PDN-mediated iron uptake surpassed uptake in
control cells by nearly

18-fold during a 30 minute exposure.

This degree of

augmentation exceeds the 3-4 fold increase of PDN-mediated iron uptake in erythroid
cells found by Savigni (75). The variability in iron uptake achievable by PDN between
our results and those of Savigni most likely reflects the specific parameters of the cell
types studied. If PDN serves as ion channel for diffusion as Savigni proposes, then cells
with higher iron content, such as erythroid cells, might not accumulate as much iron as
keratinocytes.

As

for the range of results produced between experiments

keratinocytes, the cause is unclear.

in

It is possible that subtle differences in pH of the

incubation medium from one experiment to the next are responsible.

Our incubation

buffer (HBSS) was bicarbonate-based and thus differences in time out of the incubator
may have promoted escape of CO2. Experiments using PIPES buffer (non-bicarbonate
based) demonstrate the sensitivity of iron uptake to changes in pH.
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The results of the uptake experiment were an important first step. However, the
pivotal question to our underlying goal of dermatoremediation of iron overload is
whether we can alter the iron content of keratinocytes.

We achieved a net iron

accumulation over a five-day time course by exposing cells to PDN and iron
simultaneously.

More importantly, the 3-fold augmentation of iron content persisted

through the washout period. This suggests that iron taken up by keratinocytes in vitro
can be retained. Using erythroid cells, Savigni et al demonstrated that efflux of 59Fe from
reticulocytes after PDN-stimulated uptake was negligible over several hours, unless PDN
and desferrioximine were present in the culture medium (75). Other studies of cellular
iron transport support the notion that iron can be retained after iron loading. Radioactive
iron injections in Tf iron-saturated mice persisted in liver and pancreas 14 days after
injection (57). Another study in myocardial rat cells there was no spontaneous release of
radioactive iron from cells without the presence of an iron chelator (32).

Current

understanding of intracellular iron flux helps explain this phenomenon. It is known that
iron first passes through a transient, chelatable pool of free iron before being bound and
stored by ferritin. The transit time through this pool is thought to be about one to two
hours (46, 86). After being bound by ferritin, iron is less efficiently liberated from the
cell.

Even chelators can access only a fraction of this storage iron.

One could then

predict that if enough ferritin existed to store newly delivered iron, that iron would be
unlikely to efflux spontaneously the cells.
To increase the amount of iron that could potentially be lost through the skin by
desquamation of iron-loaded keratinocytes, one must find a way to maximize it’s
accumulation.

Repeated exposures of keratinocytes to iron and PDN might increase
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storage capacity. High levels of regulatory or chelatable intracellular iron are known to
induce ferritin synthesis by stabilizing its mRNA (87).

In this way it is possible that iron

could be stored in a greater amounts without exposing the cells to a sudden overload of
the more toxic, chelatable form of iron.
Other parameters of PDN-mediated pathway were investigated to optimize iron
uptake in keratinocytes.

These experiments revealed the time- and dose-dependent

manner by which PDN-mediated iron uptake occurs. The characteristics of our time and
dose curves closely resemble those achieved by Savigini et al in studies of PDN-mediated
iron uptake in erythroid cells (75) and Morton’s findings of 67Ga uptake in CHO and
mouse 3T3 lines (76). The latter group found that maximal uptake of Ga occurred when
cells were incubated for 30 minutes with 25 uM nifedipine that had been photodegraded
using fluorescent light (76).

Our maximal uptake in terms of the greatest difference

between experimental (PDN) and control groups similarly occurred at 30 minutes.

At

this time point uptake of 59Fe was as much as 87-fold greater than basal levels. It is also
important to note that significant uptake developed rapidly. After one minute (data not
shown), there was already a 6.7-fold difference in the presence of PDN.

Interestingly,

basal iron transport (non-transferrin iron transport) followed a slightly different timeresponse curve. We expanded the control curve in four of the representative experiments
and found that there was a lag time to its development (data not shown). Increased iron
uptake occurred around 30 minutes.

This finding is somewhat discrepant with other

studies of non-transferrin bound iron uptake. However, these studies were conducted in
different cell types—fibroblasts (44) and HeLa cells (43) and at lower 59Fe concentrations
than the 15 uM that we used. If it is real, the difference we detected in the shape of the
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time-curves for non-transferrin and PDN-mediated iron transport could represent
differences in the kinetics or their mechanisms of transport; for example, carrier-mediated
vs. diffusion.
Our time curve plateaued between 60-120 minutes. The plateau could represent
one of two phenomena. Either internal storage mechanisms for iron become saturated or
the rate of iron influx equals rate of iron efflux or leakage.

Our experiments

demonstrating iron retention over a period of days makes it unlikely that significant
leakage of iron occurs during the 1-2 hours investigated during the time course.
Not only did PDN-mediated iron uptake occur expeditiously, but it also was very
sensitive to increases in iron concentration in the extracellular medium.

The dose-

response curve in the PDN-stimulated cells developed at concentrations as low as 1 uM
iron (lesser concentrations not tested) and continued to show significant uptake to 30 uM
where a plateau was just beginning.

We were particularly interested in the amount of

iron uptake occurring at physiologic and pathologic plasma iron concentrations. Normal
levels of non-Tf bound iron in plasma varies between 0-1 uM (25).

Patients with

hereditary hemochromatosis have significantly higher levels of plasma iron, usually
between 5-15 uM (55). At 1 uM 59Fe, we found a 77-fold difference in uptake in the
presence of PDN.

Greatest uptake occurred at a 5 uM concentration of iron at which

point there was a 102-fold increase in iron uptake in PDN-exposed cells. This range of
response correlates well with alleged plasma levels of iron in pathologic states of
overload.
It has been suggested that the mechanism of photodegraded nifedipine is
independent of both transferrin and non-transferrin mediated iron uptake pathways.

In
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experiments with gallium, an iron analogue, TfR+ and TfR- cells demonstrated equal
degrees of independent uptake of (>7Ga and of stimulation of uptake by PDN (76).
Savigni et al found that PDN stimulated uptake of free iron, but not transferrin-Fe in
erythroid cells (76). We attempted to eliminate the participation of transferrin-mediated
iron uptake by preincubating cells with DMEM to deplete cellular transferrin.

The

question then remained of whether the enhancement of iron uptake mediated by PDN
occurred due to actions on preexisting mechanisms of non-transferrin iron uptake. Our
investigation of iron uptake under conditions of variable pH suggests that this is not the
case.

The pH optimum for control cells, representative of non-transferrin mediated

uptake, was different from that in the presence of PDN.

This suggests that the two

pathways for iron uptake are unique. A nearly identical phenomenon has been shown in
pH studies of iron uptake in erythroid cells (75). Additionally, stimulated uptake of iron
in PDN exposed erythroid cells occurs in the presence of potent inhibitors of Fe (II)
uptake.

These findings lead to the proposition that PDN functions as a mobile iron

ionophore (76). The inhibition experiments should be tested in keratinocytes to confirm a
similar mechanism of action for PDN in this cell type.
We performed a series of experiments in stratified cell layers to investigate the
effect of cellular differentiation on iron uptake.

The iron uptake exhibited by these

stratified cells is qualitatively comparable to that seen in the keratinocytes monolayers.
During an incubation of 20 minutes in the presence of PDN, stratified cells augmented
iron uptake by 16.4-fold, as measured by cpm/ug protein to correct for increased cell
number. A similar 30 minute incubation of a proliferating monolayer demonstrated an
18-fold response (cpm/ug protein) to PDN. Essentially, then the two cell types exhibited
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the same response to iron in the presence of PDN. Differentiation state does not seem to
affect the mechanism of iron transport.

In studies of fibroblasts plated at different

densities, Kaplan et al demonstrated that rate of non-transferrin iron transport was not
affected by cellular growth state or mitogenic activity level (44).
The degree to which differentiated cells participate in iron uptake, however,
remains to be fully elucidated.

Because of the variation in incubation time it is not

possible to make conclusive statements about of the suprabasal component of the
stratified cell layers.

Our comparison of intact, stratified cell layers to detached

suprabasal cells does allow some deduction. Uptake in stratified cells greatly exceeded
that in suprabasal cells layers (16.4-fold vs. 3.7-fold). The disparity could be explained
in one of two ways. On one hand, it is possible that the suprabasal cells were unhealthy
and thus cell homeostasis and energy production was compromised, limiting iron uptake.
Alternately, if one assumes that the suprabasal layers were healthy and functioning, then
the main difference between the suprabasal cells and the stratified cells is the presence of
the basal layer in the latter.

These basal, proliferating cells could have been responsible

for the large percentage of iron uptake, with little occurring in the overlying cell layers.
There is also the possibility that contaminating basal cells remained attached to
the detached suprabasal layers.

Other means of inducing cellular differentation might

clarify

these

matters

by

reducing

confounding

factors.

Methotrexate-induced

differentation would eliminate the persistence of proliferating cells in the intact stratified
cell layers.

This would provide a source of uncontaminated differentiated cells which

could then be compared to proliferating ones.
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Some quantitative considerations are important in determining the feasibility of
using epidermal desquamation to prevent or ameliorate iron overload (see Table 1). The
numbers show that a ten-fold increase in iron elimination through the skin (0.25 mg/day
to 2.5 mg/day) would adequately prevent body iron accumulation in hereditary
hemochromatosis. Studies of iron overload suggest that some of that increase is already
provided physiologically.
saturated (64).

Epidermal iron delivery increases 3-fold when transferrin is

In patients with hereditary hemochromatosis, epidermal iron losses

increase above normal levels, although they do not compensate for unregulated intestinal
iron absorption. So the actual increase necessary through pharmacologic intervention is
probably less than the predicted 2-3 mg per day. In thalassemia major it is clear that the
iron burden of nearly 60 mg per day would probably be unmatched by dermatoremediation.

Therefore, a reduction in the frequency of desferal infusion, rather than

complete prevention, is a more reasonable therapeutic goal.
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TABLE 1. QUANTITATIVE CONSIDERATIONS

Iron absorption/excretion
In normals
Absorbed iron - 1 mg/d
Excreted iron - 1 mg/d
• Feces - 0.6 mg/d
• Urine-0.15 mg/d
•

Skin - 0.25 mg/d

Normal cellular iron content
Liver - 2.2 mg/gm (dry weight)
Epidermis - .03-0.3 mg/gm (dry
weight)

In hereditary hemochromatosis
Absorbed iron - 4 mg/d
* therefore, need to remove extra 2-3 mg/d
In transfusion iron overload (for thalassemia
major):
Patients receive 2 units RBC/wk = 400 mg
iron
Protein loss through keratinocyte
desquamation:
Normal - 1 gm/day (dry weight)
Erythroderma - 12-20 gm/day (dry
weight)

One study from the literature presents a challenge to our postulation that any iron
we are able to load into basal keratinocytes will be lost to desquamation 26-28 days later.
A study of intradermally injected radioiron, most of which was subsequently taken up by
the epidermis, found that the turnover rate of iron was slower than that of the cells.
Radiolabelled epidermal iron demonstrated a half-life of 67 days, whereas cellular
turnover was complete in 26 days (88). In attempting to explain the mechanism of this
retention the author alluded to a paper citing the extrusion and reabsorption of DNA by
mature superficial epidermal cells (89). We, on the other hand, could find no such data
about nucleic acid reutilization in this reference or elsewhere.
This evidence would suggest that calculations of skin iron loss based on the
assumption that iron turnover equals epidermal renewal time overestimate actual skin
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iron losses.

However, Cavill makes a tacit assumption that all of the intradermally

injected iron that was not cleared rapidly by plasma or lymph, entered the epidermis
directly. He did not investigate the possibility that iron was retained in the dermis, either
interstitially or bound to protein, was not investigated.

The persistence of a pool of

radioactive iron is supported by the Cavill’s own data which show an extremely slow
total body clearance of iron, lasting approximately 2 months.

If some of the

intradermally injected iron was trapped in the dermis, then the time to its ultimate
entrance into the epidermis and subsequent desquamation would have exceeded
epidermal turnover time.
Would keratinocytes be capable of safely accumulating this iron burden?

The

liver stores up to 2.2 mg iron per gram tissue without showing signs of significant
toxicity.

However, studies of patients with iron overload, suggest that different tissue

types have different thresholds of iron toxicity. Iron content in the liver of a thalassemia
double-transplant patient were four-fold the iron content of the heart (47).

What about

the sensitivity of the skin to elevated iron content? There is evidence that in states of
overload, iron exerted a mild tumor promoting activity in mouse skin by enhancing
oxidative stress (90). Iron’s ability to generate reactive oxygen species has similarly been
implicated in UV-induced skin damage (91, 87). Hyperpigmentation and dry skin are the
only other cutaneous abnormalities ever reportedly linked to iron overload (14). Despite
this information, the literature fails to any reports of increased skin tumorigenesis in HH.
Clearly future experiments would have to investigate whether optimum conditions for
increased skin iron uptake lead to the development of gross clinical signs of cutaneous
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toxicity, including scaling, lichenification, atrophy, erythema, and increased incidence of
skin tumors.
Our results give support to the notion that iron content of keratinocytes can be
significantly modified by exposure to PDN in vitro.

The pivotal next step in proving

clinical applicability would involve investigations using animal models.

It must be

shown that 1) PDN administered in vivo increases iron in the epidermis; 2) PDN can be
administered in a way that selectively increases iron the epidermis. Experiments will be
done in hairless mice (HRS/J hr/hr).

Such mice are immunologically intact and are

essentially normal but for the absence of hair.

Kathryn Morton has shown that

intraperitoneal (i.p.) injections of PDN increases gallium uptake up to 20-fold in several
internal organs (personal communication). Our initial experiments will seek to replicate
this model using the i.p. route to compare the effects of dosing-regiments on iron
accumulation.
The next goal would be to target the effects of PDN to the epidermis. The most
logical approach to this would involve the topical application of PDN.

Alternately,

nifedipine could be used as a pro-drug administered systemically and activated locally to
the epidermis by irradiating the skin. Using the guidance of data on parenteral dosing
regimens and existing data on blood flow through the skin, we will applying PDN or its
active ingredient in ethanol to one flank of hr/hr mice.

Four to five different dose

schedules can be applied to one flank with the opposite flank serving as an internal
control. To control for the possibility of systemic absorption, a separate group of mice
will serve as additional controls.
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In summary we put forth the idea of a novel pharmacologic approach to the
treatment of iron overload diseases. Our in vitro tissue culture data clearly demonstrates
the potential of PDN to alter iron uptake in keratinocytes and it has helped characterize
the parameters of the uptake.

We are hopeful that our proposed studies in vivo will

advance this pursuit by illustrating clinically applicable results.
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